Gilead(US:GILD) Yahoo Finance·2025-11-29 18:09Group 1: Company Overview - Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs globally [4] Group 2: Investment Potential - Mizuho raised its price target for Gilead from $131 to $140 while maintaining an Outperform rating, citing a longer exclusivity period for Biktarvy, now expected to last until 2036 due to generic litigation settlements [1] - The pre-exposure prophylaxis market is projected to be significantly larger than previously estimated, potentially reaching $15–20 billion [2] Group 3: Product Challenges - Gilead's cancer medication Trodelvy failed to meet its primary objective in a Phase 3 trial for HR+/HER2-negative metastatic breast cancer, as the ASCENT-07 trial did not achieve its main goal of progression-free survival [3]